Aug 2026· Journal of Proteins and Proteomics· Vol 17, pp. 267 - 290· 0 citations· 98 references
TL;DR
The novelty of this review is not another catalogue of artificial-intelligence tools or peptide delivery motifs; it is a causal evidence framework that requires four linked demonstrations: computational design provenance, experimentally measured conformational switching, quantitative delivery of intact cargo, and organelle-level functional response.
This review examines the comparative advantages of peptide-based architectures, including reduced molecular weight, access to challenging interfaces, and expansion of the addressable E3 ligase repertoire, against persistent translational barriers in proteolytic stability, membrane permeability, immunogenicity, and manu...
Walaa S. Aburayan, Ibrahim A. Alradwan, Beshair A. Alsaffar et al.· Pharmaceutics· 0 citations
This review presents a three-tiered engineering framework that systematically addresses these barriers. First, we survey chemical and sequence-based stabilization strategies, including lipidation, backbone N-methylation, and cyclization, that convert labile natural peptides into protease-resistant scaffolds. Second, mo...
Qi-Jun Xie, Hai-Ying Ma, Biao Liu et al.· Biology· 0 citations
An antitumor peptide-based delivery platform in which both termini of a stapled p53 α-helix are linked via a disulfide bond, thereby repurposing nonpolar residues originally involved in target protein (hDM2) binding as a hydrophobic block that drives co-assembly with doxorubicin.
Jae Yun Lee, Moo Chang Park, Sung-Chan Choi et al.· Small· 0 citations
This Review provides a framework for selecting disease-matched degradation routes and advancing meTPDs from platform-specific demonstrations towards predictable therapeutic modalities by integrating molecular design, receptor biology, intracellular trafficking, delivery and pharmacodynamic considerations.
Shu-Tong Lin, Hui-Ling Zhou, Jia-Yan Qiu et al.· Advanced Drug Delivery Revie...· 0 citations
Proteolysis-targeting chimeras (PROTACs) can induce degradation of otherwise challenging proteins, but their large size and unfavorable physicochemical properties often limit cellular delivery. We designed PROTAC–peptide conjugates containing a nona-arginine cell-penetrating peptide (R9), a redox-sensitive disulfide...
Maho Miyamoto, Atsuki Hirama, Kosuke Saito et al.· ACS Bio & Med Chem Au· 0 citations
Extracellular vesicle (EV) therapeutics are progressing from broad proof-of-concept studies toward product-specific engineering and clinically defined applications. Native EVs offer biological membrane functions and the capacity to transport diverse molecular cargoes, but their therapeutic performance is limited by low...
Jiao Xu, Zhi Li, Da Liu et al.· Extracellular Vesicles and C...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
